Welcome to our dedicated page for Nuvalent news (Ticker: NUVL), a resource for investors and traders seeking the latest updates and insights on Nuvalent stock.
Nuvalent, Inc. (Nasdaq: NUVL) is a clinical-stage biopharmaceutical company developing precisely targeted kinase inhibitors for oncogene-driven cancers, with a focus on non-small cell lung cancer (NSCLC). The NUVL news feed on Stock Titan aggregates company announcements, press releases, and related coverage so readers can follow how its pipeline and regulatory interactions progress over time.
According to Nuvalent’s disclosures, its lead investigational programs include zidesamtinib, a ROS1-selective inhibitor for ROS1-positive NSCLC, and neladalkib, an ALK-selective inhibitor for ALK-positive NSCLC. News items often highlight pivotal and preliminary data from the ARROS-1 and ALKOVE-1 Phase 1/2 trials, updates on the ALKAZAR Phase 3 trial in TKI-naïve ALK-positive NSCLC, and information about design features such as brain penetrance and activity against resistance mutations.
Investors and observers can also find coverage of Nuvalent’s regulatory milestones, including FDA breakthrough therapy and orphan drug designations, New Drug Application (NDA) submissions and acceptances, and PDUFA target action dates. Corporate developments such as public equity offerings, cash runway guidance, royalty arrangements on future net sales of zidesamtinib and neladalkib, and board appointments are regularly disclosed through press releases and Form 8-K filings and are reflected in the news flow.
For those tracking NUVL, this news stream provides a centralized view of clinical trial readouts, conference presentations, financing activities, and strategic updates that shape the company’s outlook in targeted oncology. Bookmarking the NUVL news page on Stock Titan can help readers quickly review new disclosures and place them in the context of Nuvalent’s broader development strategy.
Summary not available.
Summary not available.
Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company, is set to participate in the Stifel 2023 Virtual Targeted Oncology Days on April 26, 2023, at 1:30 p.m. ET. The presentation will feature CEO James Porter and CFO Alexandra Balcom.
Investors can access a live webcast on the company's website, with an archived version available for 30 days. Nuvalent focuses on developing targeted therapies for cancer, leveraging expertise in chemistry and drug design. Their pipeline includes treatments for ROS1-positive and ALK-positive non-small cell lung cancer, as well as other cancer types. The company aims to offer innovative solutions that address resistance and improve treatment outcomes.
Nuvalent, Inc. (Nasdaq: NUVL) presented new preclinical data at the AACR Annual Meeting 2023, highlighting the intracranial activity of NVL-655, a brain-penetrant ALK-selective tyrosine kinase inhibitor (TKI). The study, in collaboration with Yonsei University, demonstrates NVL-655's efficacy against treatment-resistant ALK mutations, particularly the G1202R resistance mutation. Preclinical results from a patient-derived model showed potent activity, and NVL-655 maintained selectivity over TRK to avoid adverse neurological effects. Currently under investigation in the ALKOVE-1 phase 1/2 clinical trial, NVL-655 aims to offer innovative treatment options for patients with advanced ALK-positive non-small cell lung cancer and other solid tumors.
Nuvalent, Inc. (Nasdaq: NUVL) has announced a poster presentation for its ongoing Phase 1/2 ALKOVE-1 study focusing on the ALK-selective inhibitor NVL-655. The presentation will occur at the European Lung Cancer Congress (ELCC 2023) in Copenhagen, Denmark, from March 29 to April 1, 2023. The poster details the safety and preliminary activity of NVL-655 in patients with solid tumors possessing oncogenic ALK alterations, including those with resistance mutations and CNS metastases. This first-in-human study aims to evaluate NVL-655 as an oral monotherapy, showcasing its potential to overcome limitations of current ALK inhibitors.
Nuvalent, Inc. (Nasdaq: NUVL) reported significant advancements in its pipeline of kinase inhibitors and strong financial results for 2022. The company has initiated clinical trials for NVL-520 and NVL-655 and presented preliminary data supporting NVL-520's potential best-in-class profile. Cash and equivalents stood at $472 million, anticipated to sustain operations through mid-2025. R&D expenses were $63.7 million for 2022, while the net loss increased to $81.9 million. Leadership was strengthened with promotions of Dr. Henry Pelish and Dr. John Soglia to senior vice president roles, demonstrating commitment to advancing targeted cancer therapies.
Nuvalent, Inc. (NASDAQ: NUVL), a clinical-stage biopharmaceutical company, announced a preclinical data poster presentation for its ALK-selective inhibitor, NVL-655, at the AACR Annual Meeting 2023 in Orlando, Florida, from April 14-19. The data demonstrates NVL-655's intracranial antitumor activity in a specific lung cancer model with the EML4-ALK v3 G1202R mutation. This inhibitor aims to address limitations of existing ALK inhibitors. NVL-655 is currently being explored in the ALKOVE-1 Phase 1/2 clinical trial for advanced ALK-positive non-small cell lung cancer. Full poster details will be available on Nuvalent's website post-presentation.
Nuvalent, Inc. (Nasdaq: NUVL), a biopharmaceutical company, announced participation in the 43rd Annual Cowen Healthcare Conference on March 8, 2023, at 9:10 a.m. ET in Boston. CEO James Porter, Ph.D., and CFO Alexandra Balcom will engage in a fireside chat.
A live webcast will be available in the Investors section of Nuvalent's website, with an archive accessible for 30 days post-event. Nuvalent focuses on developing targeted cancer therapies aimed at kinase targets, with ongoing programs for ROS1-positive and ALK-positive non-small cell lung cancer.
Nuvalent, Inc. (Nasdaq: NUVL) announced that CEO James Porter will present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023, at 7:30 a.m. PT in San Francisco. The company, focused on developing targeted therapies for cancer, aims to address the limitations of current treatments. A live webcast of the presentation will be available on the company's website and archived for 30 days. Nuvalent is advancing a pipeline targeting ROS1-positive and ALK-positive lung cancers, HER2 Exon 20 insertion-positive cancers, and other discovery-stage programs.
Nuvalent, Inc. (Nasdaq: NUVL) announced a manuscript publication detailing NVL-520’s design and characterization in Cancer Discovery. Currently in the ARROS-1 Phase 1/2 trial for ROS1-positive non-small cell lung cancer, NVL-520 aims to address limitations of existing ROS1 inhibitors. The publication presents extensive preclinical data and case studies showing NVL-520’s efficacy against ROS1 fusions, including the prevalent G2032R mutation, with no observed neurological toxicities. This underscores NVL-520's potential as a best-in-class ROS1 inhibitor.